Identification
NameCalcitriol
Accession NumberDB00136  (NUTR00003, APRD00246, DB05314)
TypeSmall Molecule
GroupsApproved, Nutraceutical
Description

Calcitriol or 1,25-dihydroxycholecalciferol (abbreviated 1,25-(OH)2-D3) is the active form of vitamin D found in the body (vitamin D3). Calcitriol is marketed under various trade names including Rocaltrol (Roche), Calcijex (Abbott) and Decostriol (Mibe, Jesalis). It is produced in the kidneys via 25-hydroxyvitamin D-1 α-hydroxylase by conversion from 25-hydroxycholecalciferol (calcidiol). This is stimulated by a decrease in serum calcium, phosphate (PO43−) and parathyroid hormone (PTH) levels. It regulates calcium levels by increasing the absorption of calcium and phosphate from the gastrointestinal tract, increasing calcium and phosphate reabsorption in the kidneys and inhibiting the release of PTH. Calcitriol is also commonly used as a medication in the treatment of hypocalcemia and osteoporosis.

Structure
Thumb
Synonyms
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol
(1α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(5Z,7E)-(1S,3R)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
1-alpha-25-Dihydroxyvitamin D3
1,25-DHCC
1,25-dihydroxycholecalciferol
1α,25-dihydroxycholecalciferol
1α,25-dihydroxyvitamin D3
1α,25(OH)2D3
Calcitriol
Calcitriolum
External IDs DN-101 / RO 21-5535 / RO-21-5535 / RO-215535
Product Ingredients Not Available
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CalcijexInjection, solution1 ug/mLIntravenousAbbvie2010-06-012017-05-20Us
CalcijexSolution1 mcgIntravenousAbbvie1990-12-312017-01-13Canada
CalcijexSolution2 mcgIntravenousAbbvie1990-12-312017-01-13Canada
CalcitriolCapsule.25 ug/1OralDispensing Solutions, Inc.2009-08-26Not applicableUs
CalcitriolOintment3 ug/gTopicalPerrigo New York Inc.2012-03-08Not applicableUs
CalcitriolSolution1 ug/mLOralRanbaxy Inc.2009-08-26Not applicableUs
CalcitriolCapsule.25 ug/1OralCarilion Materials Management2009-08-26Not applicableUs
CalcitriolCapsule.25 ug/1OralRanbaxy Inc.2009-08-26Not applicableUs
CalcitriolCapsule.25 ug/1OralAphena Pharma Solutions Tennessee, Inc.2009-08-26Not applicableUs
CalcitriolCapsule.5 ug/1OralRanbaxy Inc.2009-08-26Not applicableUs63304 0240 01 nlmimage10 4d3da69d
Calcitriol InjectionSolution1 mcgIntravenousFresenius Kabi2003-07-07Not applicableCanada
Calcitriol Injection USPSolution2 mcgIntravenousSterimax Inc2015-04-16Not applicableCanada
Calcitriol Injection USPSolution1 mcgIntravenousSterimax Inc2015-03-27Not applicableCanada
Calcitriol-odanCapsule0.5 mcgOralOdan Laboratories Ltd2014-10-10Not applicableCanada
Calcitriol-odanCapsule0.25 mcgOralOdan Laboratories Ltd2014-10-10Not applicableCanada
RocaltrolSolution1 ug/mLOralValidus Pharmaceuticals2009-07-23Not applicableUs
RocaltrolCapsule, gelatin coated.5 ug/1OralKaiser Foundations Hospitals2010-06-04Not applicableUs
RocaltrolCapsule, gelatin coated.25 ug/1OralValidus Pharmaceuticals2009-08-10Not applicableUs
RocaltrolCapsule, gelatin coated.25 ug/1OralAphena Pharma Solutions Tennessee, Inc.2009-08-10Not applicableUs
RocaltrolCapsule, gelatin coated.25 ug/1OralKaiser Foundations Hospitals2010-08-09Not applicableUs
RocaltrolCapsule, gelatin coated.5 ug/1OralValidus Pharmaceuticals2009-08-10Not applicableUs
Rocaltrol Cap 0.25mcgCapsule0.25 mcgOralHoffmann La Roche1979-12-31Not applicableCanada
Rocaltrol Cap 0.5mcgCapsule0.5 mcgOralHoffmann La Roche1979-12-31Not applicableCanada
Rocaltrol Oral Solution 1mcg/mlSolution1 mcgOralHoffmann La Roche1992-12-312013-06-24Canada
SilkisOintment3 mcgTopicalGalderma2010-04-09Not applicableCanada
VecticalOintment3 ug/gTopicalGalderma2009-02-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CalcitriolInjection1 ug/mLIntravenousWest Ward Pharmaceutical2006-02-08Not applicableUs
CalcitriolInjection, solution1 mg/mLIntravenousPhysicians Total Care, Inc.2011-05-17Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralTeva2001-10-152017-07-31Us
CalcitriolCapsule, liquid filled.5 ug/1OralHeritage2013-05-29Not applicableUs23155 0119 01 nlmimage10 6f3fb7ed
CalcitriolSolution1 ug/mLOralWest Ward Pharmaceutical2003-07-18Not applicableUs
CalcitriolCapsule.5 ug/1OralAmneal Pharmaceuticals2017-06-18Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralGolden State Medical Supply2014-12-26Not applicableUs23155 0118 01 nlmimage10 ef3977fb
CalcitriolCapsule.5 ug/1OralStrides Shasun Limited2014-12-12Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralPhysicians Total Care, Inc.2005-12-02Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralAphena Pharma Solutions Tennessee, Inc.2013-05-29Not applicableUs
CalcitriolInjection, solution1 ug/mLIntravenousAmerican Regent2005-03-14Not applicableUs
CalcitriolInjection2 ug/mLIntravenousAkorn2011-10-14Not applicableUs
CalcitriolCapsule.25 ug/1OralAmerincan Health Packaging2012-03-012016-11-30Us
CalcitriolCapsule.25 ug/1OralAtlantic Biologicals Corps.2014-12-12Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralTeva2016-08-25Not applicableUs
CalcitriolCapsule.5 ug/1Oralbryant ranch prepack2014-12-12Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralKaiser Foundations Hospitals2015-12-03Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralCardinal Health2009-10-29Not applicableUs00093 0657 01 nlmimage10 f137f88f
CalcitriolCapsule, liquid filled.5 ug/1OralTeva2001-10-152017-10-31Us
CalcitriolCapsule.25 ug/1OralAphena Pharma Solutions Tennessee, Inc.2006-03-27Not applicableUs
CalcitriolCapsule, liquid filled.5 ug/1OralGolden State Medical Supply2014-12-26Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralCardinal Health2016-08-25Not applicableUs
CalcitriolInjection1 ug/mLIntravenousAkorn2013-03-22Not applicableUs
CalcitriolCapsule, liquid filled.25 ug/1OralHeritage2013-05-29Not applicableUs
CalcitriolCapsule.25 ug/1OralWest Ward Pharmaceutical2006-03-27Not applicableUs00054 0007 25 nlmimage10 6f3fb7bd
CalcitriolCapsule.25 ug/1OralAmneal Pharmaceuticals2017-06-18Not applicableUs
CalcitriolCapsule, liquid filled.5 ug/1OralTeva2016-07-01Not applicableUs
CalcitriolCapsule, liquid filled.5 ug/1OralKaiser Foundations Hospitals2015-12-03Not applicableUs
CalcitriolCapsule, liquid filled.5 ug/1OralCardinal Health2009-10-29Not applicableUs00093 0658 01 nlmimage10 2b2b15c8
CalcitriolCapsule.25 ug/1OralStrides Shasun Limited2014-12-12Not applicableUs
CalcitriolCapsule, liquid filled.5 ug/1OralPhysicians Total Care, Inc.2010-03-01Not applicableUs
CalcitriolInjection1 ug/mLIntravenousAkorn2011-10-14Not applicableUs
CalcitriolInjection, solution1 ug/mLIntravenousFresenius Kabi2003-05-29Not applicableUs
CalcitriolCapsule, liquid filled.5 ug/1OralAvera Mc Kennan Hospital2016-10-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AsentarNot Available
Calcitriol Oral SolutionRoxane
DecostriolMibe Jena (Germany), Jesalis (Hong Kong, Thailand)
Brand mixturesNot Available
Categories
UNIIFXC9231JVH
CAS number32222-06-3
WeightAverage: 416.6365
Monoisotopic: 416.329045274
Chemical FormulaC27H44O3
InChI KeyGMRQFYUYWCNGIN-NKMMMXOESA-N
InChI
InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1
IUPAC Name
(1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol
SMILES
C[[email protected]](CCCC(C)(C)O)[[email protected]@]1([H])CC[[email protected]@]2([H])\C(CCC[[email protected]]12C)=C\C=C1\C[[email protected]@H](O)C[[email protected]](O)C1=C
Pharmacology
Indication

Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.

Structured Indications
Pharmacodynamics

Calcitriol, a pharmaceutical form of vitamin D, has anti-osteoporotic, immunomodulatory, anticarcinogenic, antipsoriatic, antioxidant, and mood-modulatory activities. Calcitriol has been found to be effective in the treatment of psoriasis when applied topically. Calcitriol has been found to induce differentiation and/or inhibit cell proliferation in a number of malignant cell lines including human prostate cancer cells. Vitamin D deficiency has long been suspected to increase the susceptibility to tuberculosis. The active form of calcitriol, 1,25-(OH)2-D3, has been found to enhance the ability of mononuclear phagocytes to suppress the intracellular growth of Mycobacterium tuberculosis. 1,25-(OH)2-D3 has demonstrated beneficial effects in animal models of such autoimmune diseases as rheumatoid arthritis. It has also been found to induce monocyte differentiation and to inhibit lymphocyte proliferation and production of cytokines, including interleukin IL-1 and IL-2, as well as to suppress immunoglobulin secretion by B lymphocytes. Vitamin D appears to demonstrate both immune-enhancing and immunosuppressive effects.

Mechanism of action

The mechanism of action of calcitriol in the treatment of psoriasis is accounted for by their antiproliferative activity for keratinocytes and their stimulation of epidermal cell differentiation. The anticarcinogenic activity of the active form of Calcitriol appears to be correlated with cellular vitamin D receptor (VDR) levels. Vitamin D receptors belong to the superfamily of steroid-hormone zinc-finger receptors. VDRs selectively bind 1,25-(OH)2-D3 and retinoic acid X receptor (RXR) to form a heterodimeric complex that interacts with specific DNA sequences known as vitamin D-responsive elements. VDRs are ligand-activated transcription factors. The receptors activate or repress the transcription of target genes upon binding their respective ligands. It is thought that the anticarcinogenic effect of Calcitriol is mediated via VDRs in cancer cells. The immunomodulatory activity of calcitriol is thought to be mediated by vitamin D receptors (VDRs) which are expressed constitutively in monocytes but induced upon activation of T and B lymphocytes. 1,25-(OH)2-D3 has also been found to enhance the activity of some vitamin D-receptor positive immune cells and to enhance the sensitivity of certain target cells to various cytokines secreted by immune cells.

TargetKindPharmacological actionActionsOrganismUniProt ID
Vitamin D3 receptorProteinyes
antagonist
HumanP11473 details
Homeobox protein Hox-A10ProteinunknownNot AvailableHumanP31260 details
Vitamin D-binding proteinProteinunknownNot AvailableHumanP02774 details
Related Articles
Absorption

Rapidly absorbed from the intestine.

Volume of distributionNot Available
Protein binding

99.9%

Metabolism

The first pathway involves 24-hydroxylase activity in the kidney; this enzyme is also present in many target tissues which possess the vitamin D receptor such as the intestine. The end product of this pathway is a side chain shortened metabolite, calcitroic acid. The second pathway involves the conversion of calcitriol via the stepwise hydroxylation of carbon-26 and carbon-23, and cyclization to yield ultimately 1a,25R(OH)2-26,23S-lactone D3. The lactone appears to be the major metabolite circulating in humans.

SubstrateEnzymesProduct
Calcitriol
Not Available
Calcitroic acidDetails
Route of elimination

Enterohepatic recycling and biliary excretion of calcitriol occur. The metabolites of calcitriol are excreted primarily in feces. Cumulative excretion of radioactivity on the sixth day following intravenous administration of radiolabeled calcitriol averaged 16% in urine and 49% in feces.

Half life

5-8 hours

Clearance
  • 15.3 mL/hr/kg [pediatric patients (age range: 1.8 to 16 years) undergoing peritoneal dialysis receiving dose of 10.2 ng/kg (SD 5.5 ng/kg) for 2 months]
Toxicity

LD50 (oral, rat) = 620 μg/kg; LD50 (intraperitoneal, rat) > 5 mg/kg; Overdose evident in elevated blood calcium levels causing symptoms of anorexia, nausea and vomiting, polyuria, polydipsia, weakness, pruritus, and nervousness, potentially with irreversible calcification of soft tissue in the kidney and liver.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with 5-androstenedione.Experimental, Illicit
AcetyldigitoxinCalcitriol may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AlclometasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Alclometasone.Approved
AldosteroneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Aldosterone.Experimental
AlfacalcidolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Alfacalcidol.Approved, Nutraceutical
Aluminum hydroxideThe serum concentration of Aluminum hydroxide can be increased when it is combined with Calcitriol.Approved
AmcinonideThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Amcinonide.Approved
AmiodaroneThe metabolism of Calcitriol can be decreased when combined with Amiodarone.Approved, Investigational
AndrostenedioneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with 4-Androstenedione.Experimental, Illicit
AnecortaveThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Anecortave.Investigational
AprepitantThe serum concentration of Calcitriol can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Calcitriol.Approved, Investigational
AtazanavirThe metabolism of Calcitriol can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Calcitriol can be decreased when combined with Atomoxetine.Approved
Beclomethasone dipropionateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Beclomethasone dipropionate.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypercalcemic activities of Calcitriol.Approved
BetamethasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BexaroteneThe serum concentration of Calcitriol can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Calcitriol can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Calcitriol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Calcitriol can be decreased when it is combined with Bosentan.Approved, Investigational
BudesonideThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Budesonide.Approved
CalcidiolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Calcipotriol.Approved
CalciumThe risk or severity of adverse effects can be increased when Calcium is combined with Calcitriol.Nutraceutical
Calcium AcetateThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Calcitriol.Approved
Calcium CarbonateThe risk or severity of adverse effects can be increased when Calcium carbonate is combined with Calcitriol.Approved
Calcium ChlorideThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Calcitriol.Approved
Calcium CitrateThe risk or severity of adverse effects can be increased when Calcium citrate is combined with Calcitriol.Approved
Calcium glubionateThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Calcitriol.Approved
Calcium GluceptateThe risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Calcitriol.Approved
Calcium gluconateThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Calcitriol.Approved, Vet Approved
CarbamazepineThe metabolism of Calcitriol can be increased when combined with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Calcitriol can be increased when it is combined with Ceritinib.Approved
ChlorothiazideChlorothiazide may increase the hypercalcemic activities of Calcitriol.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypercalcemic activities of Calcitriol.Approved
CholecalciferolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineThe serum concentration of Calcitriol can be decreased when it is combined with Cholestyramine.Approved
CiclesonideThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Ciclesonide.Approved, Investigational
ClarithromycinThe metabolism of Calcitriol can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Calcitriol can be decreased when combined with Clemastine.Approved
ClobetasolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Clobetasol.Investigational
Clobetasol propionateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Clobetasol propionate.Approved
ClocortoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Clocortolone.Approved
ClotrimazoleThe metabolism of Calcitriol can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Calcitriol can be decreased when combined with Cobicistat.Approved
ColesevelamThe serum concentration of Calcitriol can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Calcitriol can be decreased when it is combined with Colestipol.Approved
ConivaptanThe serum concentration of Calcitriol can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Cortisone acetate.Approved
CrizotinibThe metabolism of Calcitriol can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Calcitriol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Calcitriol can be decreased when it is combined with Dabrafenib.Approved
DanazolDanazol may increase the hypercalcemic activities of Calcitriol.Approved
DarunavirThe metabolism of Calcitriol can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Calcitriol can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Calcitriol can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Calcitriol can be decreased when combined with Delavirdine.Approved
DeslanosideCalcitriol may increase the arrhythmogenic activities of Deslanoside.Approved
DesoximetasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Desoximetasone.Approved
Desoxycorticosterone acetateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Dexamethasone isonicotinate.Vet Approved
DiflorasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Diflorasone.Approved
DifluocortoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Difluocortolone.Approved
DifluprednateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Difluprednate.Approved
DigitoxinCalcitriol may increase the arrhythmogenic activities of Digitoxin.Approved
DigoxinCalcitriol may increase the arrhythmogenic activities of Digoxin.Approved
DihydroergotamineThe metabolism of Calcitriol can be decreased when combined with Dihydroergotamine.Approved
DihydrotachysterolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Dihydrotachysterol.Approved
DiltiazemThe metabolism of Calcitriol can be decreased when combined with Diltiazem.Approved
DoxercalciferolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Doxercalciferol.Approved
DoxycyclineThe metabolism of Calcitriol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Calcitriol can be decreased when combined with Dronedarone.Approved
EfavirenzThe serum concentration of Calcitriol can be decreased when it is combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Calcitriol can be decreased when it is combined with Enzalutamide.Approved
EquileninThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Equilenin.Experimental
EquilinThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Equilin.Approved
ErgocalciferolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Ergocalciferol.Approved, Nutraceutical
ErythromycinThe metabolism of Calcitriol can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Calcitriol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstroneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Estrone.Approved
Estrone sulfateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Estrone sulfate.Approved
EtravirineThe serum concentration of Calcitriol can be decreased when it is combined with Etravirine.Approved
fluasteroneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with fluasterone.Investigational
FluconazoleThe metabolism of Calcitriol can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fludrocortisone.Approved
FlumethasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Flumethasone.Approved, Vet Approved
FlunisolideThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluocinonide.Approved, Investigational
FluocortoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluocortolone.Approved, Withdrawn
FluorometholoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluorometholone.Approved
FluprednideneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluprednisolone.Approved
FlurandrenolideThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Flurandrenolide.Approved
Fluticasone furoateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluticasone furoate.Approved
Fluticasone propionateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Calcitriol can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Calcitriol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Calcitriol can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Calcitriol can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Calcitriol can be increased when it is combined with Fusidic Acid.Approved
HE3286The therapeutic efficacy of Calcitriol can be decreased when used in combination with HE3286.Investigational
HydrochlorothiazideHydrochlorothiazide may increase the hypercalcemic activities of Calcitriol.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Calcitriol.Approved, Illicit
HydrocortisoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypercalcemic activities of Calcitriol.Approved
IdelalisibThe serum concentration of Calcitriol can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Calcitriol can be decreased when combined with Imatinib.Approved
IndapamideIndapamide may increase the hypercalcemic activities of Calcitriol.Approved
IndinavirThe metabolism of Calcitriol can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Calcitriol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Calcitriol can be decreased when combined with Isradipine.Approved
IstaroximeThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Istaroxime.Investigational
ItraconazoleThe metabolism of Calcitriol can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Calcitriol can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Calcitriol can be decreased when combined with Ketoconazole.Approved, Investigational
LopinavirThe metabolism of Calcitriol can be decreased when combined with Lopinavir.Approved
LovastatinThe metabolism of Calcitriol can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Calcitriol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Calcitriol can be increased when combined with Lumacaftor.Approved
Magnesium HydroxideThe serum concentration of Magnesium hydroxide can be increased when it is combined with Calcitriol.Approved
Magnesium oxideThe serum concentration of Magnesium oxide can be increased when it is combined with Calcitriol.Approved
Magnesium salicylateThe serum concentration of Magnesium salicylate can be increased when it is combined with Calcitriol.Approved
Magnesium SulfateThe serum concentration of Magnesium Sulfate can be increased when it is combined with Calcitriol.Approved, Vet Approved
ME-609The therapeutic efficacy of Calcitriol can be decreased when used in combination with ME-609.Investigational
MedrysoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Medrysone.Approved
MelengestrolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Melengestrol.Vet Approved
MethyclothiazideMethyclothiazide may increase the hypercalcemic activities of Calcitriol.Approved
MethylprednisoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MetolazoneMetolazone may increase the hypercalcemic activities of Calcitriol.Approved
MifepristoneThe serum concentration of Calcitriol can be increased when it is combined with Mifepristone.Approved, Investigational
Mineral oilThe serum concentration of Calcitriol can be decreased when it is combined with Mineral oil.Approved, Vet Approved
MitotaneThe serum concentration of Calcitriol can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Calcitriol can be decreased when it is combined with Modafinil.Approved, Investigational
MometasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Mometasone.Approved, Vet Approved
NafcillinThe serum concentration of Calcitriol can be decreased when it is combined with Nafcillin.Approved
NCX 1022The therapeutic efficacy of Calcitriol can be decreased when used in combination with NCX 1022.Investigational
NefazodoneThe metabolism of Calcitriol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Calcitriol can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Calcitriol can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Calcitriol can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Calcitriol can be decreased when combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Calcitriol.Approved
OlaparibThe metabolism of Calcitriol can be decreased when combined with Olaparib.Approved
OleandrinCalcitriol may increase the arrhythmogenic activities of Anvirzel.Experimental
Oleoyl-estroneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Oleoyl estrone.Investigational
OrlistatThe serum concentration of Calcitriol can be decreased when it is combined with Orlistat.Approved, Investigational
OsimertinibThe serum concentration of Calcitriol can be increased when it is combined with Osimertinib.Approved
OuabainCalcitriol may increase the arrhythmogenic activities of Ouabain.Approved
PalbociclibThe serum concentration of Calcitriol can be increased when it is combined with Palbociclib.Approved
ParamethasoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Paramethasone.Approved
ParicalcitolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Paricalcitol.Approved, Investigational
PentobarbitalThe metabolism of Calcitriol can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Calcitriol can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Calcitriol can be increased when combined with Phenytoin.Approved, Vet Approved
PolythiazidePolythiazide may increase the hypercalcemic activities of Calcitriol.Approved
PosaconazoleThe metabolism of Calcitriol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with dehydroepiandrosterone sulfate.Investigational
PrednicarbateThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prednicarbate.Approved
PrednisoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prednisone.Approved, Vet Approved
PregnenoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Pregnenolone.Experimental
PrimidoneThe metabolism of Calcitriol can be increased when combined with Primidone.Approved, Vet Approved
QuinethazoneQuinethazone may increase the hypercalcemic activities of Calcitriol.Approved
RanolazineThe metabolism of Calcitriol can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Calcitriol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Calcitriol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Calcitriol can be increased when combined with Rifapentine.Approved
RimexoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Rimexolone.Approved
RitonavirThe metabolism of Calcitriol can be decreased when combined with Ritonavir.Approved, Investigational
SaquinavirThe metabolism of Calcitriol can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Calcitriol.Approved
SevelamerThe serum concentration of Calcitriol can be decreased when it is combined with Sevelamer.Approved
SildenafilThe metabolism of Calcitriol can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Calcitriol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Calcitriol can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Calcitriol can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Calcitriol can be increased when it is combined with Stiripentol.Approved
SucralfateThe serum concentration of Sucralfate can be increased when it is combined with Calcitriol.Approved
SulfisoxazoleThe metabolism of Calcitriol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TelaprevirThe metabolism of Calcitriol can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Calcitriol can be decreased when combined with Telithromycin.Approved
TiclopidineThe metabolism of Calcitriol can be decreased when combined with Ticlopidine.Approved
TixocortolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Tixocortol.Approved
TocilizumabThe serum concentration of Calcitriol can be decreased when it is combined with Tocilizumab.Approved
TriamcinoloneThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypercalcemic activities of Calcitriol.Approved, Vet Approved
VenlafaxineThe metabolism of Calcitriol can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Calcitriol can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Calcitriol can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Calcitriol can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Raymond E. Conrow, "Process for preparation of calcitriol lactone and related intermediates." U.S. Patent US5457245, issued April, 1994.

US5457245
General References
  1. Brawer MK: Recent Progress in the Treatment of Advanced Prostate Cancer With Intermittent Dose-Intense Calcitriol (DN-101). Rev Urol. 2007 Winter;9(1):1-8. [PubMed:17396166 ]
  2. Beer TM, Javle M, Lam GN, Henner WD, Wong A, Trump DL: Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res. 2005 Nov 1;11(21):7794-9. [PubMed:16278401 ]
External Links
ATC CodesA11CC04 — CalcitriolD05AX03 — Calcitriol
AHFS Codes
  • 88:16.00
PDB EntriesNot Available
FDA labelDownload (39.2 KB)
MSDSDownload (74.7 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedNot AvailableAnemia of Chronic Disease / Chronic Kidney Disease (CKD)1
0TerminatedTreatmentDeficiency, Vitamin D / Hypertensive1
1Active Not RecruitingPreventionCancer, Breast / Cancer, Ovarian / Cancers / Cervical Cancers / Endometrial Cancers / Primary Peritoneal Carcinoma / Sarcoma, Bone / Tumors, Solid1
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailablePostmenopausal Osteoporosis, Multiple Sites / To Study the Safety and Tolerability of 2MD in Postmenopausal Women, the Intended Target Population1
1CompletedPreventionAdenocarcinomas / Colorectal Adenomas / Colorectal Polyps1
1CompletedTreatmentNeoplasms1
1CompletedTreatmentPlaque Psoriasis / Psoriasis1
1, 2CompletedBasic ScienceMouth Neoplasms1
1, 2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2Active Not RecruitingPreventionBone Loss / Calcifications, Vascular / End Stage Renal Disease (ESRD) / Fracture Bone / Transplantation, Kidney1
2Active Not RecruitingPreventionCancer, Breast1
2Active Not RecruitingTreatmentKlinefelter's Syndrome / Male Infertility / Y-chromosome Microdeletions1
2CompletedNot AvailableDiabetes, Diabetes Mellitus Type 11
2CompletedPreventionBone and Bones / Neoplasms, Breast1
2CompletedPreventionDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentBasal Cell Carcinoma (BCC)1
2CompletedTreatmentChronic Plaque Psoriasis1
2CompletedTreatmentEnd Stage Renal Disease (ESRD) / Renal Osteodystrophy1
2CompletedTreatmentHyperparathyroidism, Secondary / Renal Osteodystrophy1
2CompletedTreatmentMyelodysplastic Syndromes1
2CompletedTreatmentPlaque-Type Psoriasis1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentSevere Sepsis or Septic Shock1
2CompletedTreatmentParathyroid deficiency1
2RecruitingPreventionAcute Kidney Injury (AKI) / Critically Ill1
2RecruitingTreatmentCastration-Resistant Prostate Cancer (CRPC)1
2SuspendedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentHypocalcemia1
2TerminatedTreatmentHypocalcemia / Hypovitaminosis D1
2TerminatedTreatmentProstate Cancer / Prostatic Neoplasms1
2Unknown StatusTreatmentAdvanced Intrahepatic Cholangiocarcinoma1
2Unknown StatusTreatmentMyelodysplastic Syndrome1
2Unknown StatusTreatmentSystemic Lupus Erythematosus (SLE)1
2, 3Unknown StatusTreatmentProstate Cancer1
3CompletedPreventionBone destruction / Cardiac Transplantation1
3CompletedTreatmentChronic Kidney Disease (CKD) / Deficiency, Vitamin D / Hyperparathyroidism, Secondary1
3CompletedTreatmentFacial Angiofibroma1
3CompletedTreatmentOsteopetrosis1
3RecruitingTreatmentDiabetic Nephropathies1
3RecruitingTreatmentSecondary Hyperparathyroidism-Chronic Kidney Disease1
3TerminatedTreatmentProstate Cancer1
4CompletedPreventionChronic Kidney Disease (CKD) / Coronary Calcification / Deficiency, Vitamin D / Disorders of Calcium and Bone Metabolism1
4CompletedTreatmentAnemias / Chronic Kidney Disease (CKD)1
4CompletedTreatmentCardiorenal Syndrome / Chronic Allograft Nephropathy (CAN)1
4CompletedTreatmentChronic Kidney Disease (CKD) / Hyperparathyroidism, Secondary2
4CompletedTreatmentDeficiency, Vitamin D1
4CompletedTreatmentEnd Stage Renal Disease (ESRD) / Hyperparathyroidism, Secondary1
4CompletedTreatmentIgA Nephropathy1
4CompletedTreatmentPityriasis Alba1
4CompletedTreatmentPostmenopausal Osteoporosis (PMO)1
4CompletedTreatmentStage 3 Chronic Kidney Disease1
4Not Yet RecruitingPreventionChronic Kidney Disease Stage 1 / Chronic Kidney Disease Stage 21
4RecruitingTreatmentInfertilities1
4RecruitingTreatmentPsoriasis Vulgaris1
4TerminatedTreatmentDialysis therapy / Hyperparathyroidism, Secondary1
4TerminatedTreatmentEnd-Stage Kidney Disease1
4TerminatedTreatmentHypercalcemia / Hyperparathyroidism, Secondary / Hyperphosphataemia / Renal Failure1
4Unknown StatusScreeningDiabetic Nephropathies1
4Unknown StatusTreatmentAsthma Bronchial1
4Unknown StatusTreatmentAutoimmune Diseases / Glomerulonephritis1
4Unknown StatusTreatmentChronic Kidney Disease (CKD) / Proteinuria1
4Unknown StatusTreatmentProteinuria1
4Unknown StatusTreatmentBone destruction1
4WithdrawnTreatmentNephritis / Proteinuria / Systemic Lupus Erythematosus (SLE)1
Not AvailableActive Not RecruitingPreventionLung Cancers / Precancerous Conditions / Tobacco Use Disorders1
Not AvailableCompletedPreventionBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentArterial Dysfunction / Chronic Kidney Disease (CKD)1
Not AvailableCompletedTreatmentCrohn's Disease (CD) / Rheumatoid Arthritis1
Not AvailableCompletedTreatmentHIV Seropositive1
Not AvailableCompletedTreatmentHyperparathyroidism, Secondary / Hypocalcemia1
Not AvailableCompletedTreatmentHyperparathyroidism / Kidney Diseases1
Not AvailableCompletedTreatmentIgA Nephropathy1
Not AvailableCompletedTreatmentPsoriasis2
Not AvailableTerminatedNot AvailableEnd-Stage Renal Disease (ESRD) / Hyperparathyroidism, Secondary1
Not AvailableUnknown StatusNot AvailableNeoplasms, Breast / Postmenopausal Disorder1
Not AvailableUnknown StatusTreatmentProstatic Neoplasms1
Not AvailableWithdrawnTreatmentChronic Kidney Disease (CKD) / Deficiency, Vitamin D1
Not AvailableWithdrawnTreatmentHypertensive1
Pharmacoeconomics
Manufacturers
  • Roxane laboratories inc
  • Teva pharmaceuticals usa inc
  • Validus pharmaceuticals llc
  • Abbott laboratories hosp products div
  • Akorn inc
  • App pharmaceuticals llc
  • Fresenius medical care north america
  • Genix therapeutics inc
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Lyne laboratories inc
  • Teva parenteral medicines inc
  • Galderma laboratories lp
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous1 ug/mL
CapsuleOral.25 ug/1
CapsuleOral.5 ug/1
Capsule, liquid filledOral.25 ug/1
Capsule, liquid filledOral.5 ug/1
InjectionIntravenous1 ug/mL
InjectionIntravenous2 ug/mL
Injection, solutionIntravenous1 mg/mL
SolutionIntravenous1 mcg
SolutionIntravenous2 mcg
Capsule, gelatin coatedOral.25 ug/1
Capsule, gelatin coatedOral.5 ug/1
SolutionOral1 ug/mL
CapsuleOral0.25 mcg
CapsuleOral0.5 mcg
SolutionOral1 mcg
OintmentTopical3 mcg
OintmentTopical3 ug/g
Prices
Unit descriptionCostUnit
Calcijex 2 mcg/ml19.38USD ml
Calcijex 1 mcg/ml ampul14.7USD ml
Calcijex 1 mcg/ml10.68USD ml
Calcitriol 1 mcg/ml ampul6.0USD ml
Vectical 3 mcg/g ointment4.68USD g
Rocaltrol 0.5 mcg capsule2.02USD capsule
Calcitriol 0.5 mcg capsule1.97USD capsule
Rocaltrol 0.25 mcg capsule1.46USD capsule
Calcitriol 0.25 mcg capsule1.45USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6265392 Yes2000-02-022020-02-02Us
US6051567 Yes2000-02-022020-02-02Us
US6274169 Yes2000-02-022020-02-02Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)113-114Uskokovic, M.R., Narwid, T.A., lacobelli, J.A. and Baggiolini, E.; U.S. Patent 3,993,675; November 23, 1976; assigned to Hoffmann-La Roche, Inc.
water solubilityInsolubleNot Available
logP5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00667 mg/mLALOGPS
logP5.51ALOGPS
logP4.35ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)14.39ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area60.69 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity126.53 m3·mol-1ChemAxon
Polarizability51.02 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9924
Blood Brain Barrier+0.8524
Caco-2 permeable+0.7812
P-glycoprotein substrateSubstrate0.7843
P-glycoprotein inhibitor INon-inhibitor0.6065
P-glycoprotein inhibitor IINon-inhibitor0.6073
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8367
CYP450 2D6 substrateNon-substrate0.9022
CYP450 3A4 substrateSubstrate0.7506
CYP450 1A2 substrateNon-inhibitor0.9033
CYP450 2C9 inhibitorNon-inhibitor0.8354
CYP450 2D6 inhibitorNon-inhibitor0.9495
CYP450 2C19 inhibitorNon-inhibitor0.7796
CYP450 3A4 inhibitorNon-inhibitor0.813
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6175
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9274
BiodegradationNot ready biodegradable0.9937
Rat acute toxicity5.1352 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8734
hERG inhibition (predictor II)Non-inhibitor0.8579
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassVitamin D and derivatives
Direct ParentVitamin D and derivatives
Alternative ParentsTriterpenoids / Tertiary alcohols / Secondary alcohols / Cyclic alcohols and derivatives / Hydrocarbon derivatives
SubstituentsTriterpenoid / Tertiary alcohol / Cyclic alcohol / Secondary alcohol / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Alcohol / Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptorstriol, D3 vitamins, hydroxycalciol (CHEBI:17823 ) / Steroid hormones (C01673 ) / Vitamin D3 and derivatives (LMST03020258 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B/WSTF which mediates the interaction with acetylated histones, an essential step for VDR-promoter association. Plays a central role in calcium homeostasis.
Gene Name:
VDR
Uniprot ID:
P11473
Uniprot Name:
Vitamin D3 receptor
Molecular Weight:
48288.64 Da
References
  1. Reinhart GA: Vitamin D analogs: novel therapeutic agents for cardiovascular disease? Curr Opin Investig Drugs. 2004 Sep;5(9):947-51. [PubMed:15503649 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. Binds to the DNA sequence 5'-AA[AT]TTTTATTAC-3'.
Specific Function:
Histone deacetylase binding
Gene Name:
HOXA10
Uniprot ID:
P31260
Uniprot Name:
Homeobox protein Hox-A10
Molecular Weight:
42413.825 Da
References
  1. Du H, Daftary GS, Lalwani SI, Taylor HS: Direct regulation of HOXA10 by 1,25-(OH)2D3 in human myelomonocytic cells and human endometrial stromal cells. Mol Endocrinol. 2005 Sep;19(9):2222-33. Epub 2005 May 19. [PubMed:15905361 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Vitamin transporter activity
Specific Function:
Involved in vitamin D transport and storage, scavenging of extracellular G-actin, enhancement of the chemotactic activity of C5 alpha for neutrophils in inflammation and macrophage activation.
Gene Name:
GC
Uniprot ID:
P02774
Uniprot Name:
Vitamin D-binding protein
Molecular Weight:
52963.025 Da
References
  1. Arnaud J, Constans J: Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet. 1993 Sep;92(2):183-8. [PubMed:8370586 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxidoreductase activity
Specific Function:
Has a role in maintaining calcium homeostasis. Catalyzes the NADPH-dependent 24-hydroxylation of calcidiol (25-hydroxyvitamin D(3)) and calcitriol (1-alpha,25-dihydroxyvitamin D(3)). The enzyme can perform up to 6 rounds of hydroxylation of calcitriol leading to calcitroic acid. It also shows 23-hydroxylating activity leading to 1-alpha,25-dihydroxyvitamin D(3)-26,23-lactone as end product.
Gene Name:
CYP24A1
Uniprot ID:
Q07973
Uniprot Name:
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial
Molecular Weight:
58874.695 Da
References
  1. Schuster I: Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011 Jan;1814(1):186-99. doi: 10.1016/j.bbapap.2010.06.022. Epub 2010 Jul 7. [PubMed:20619365 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, Sakaki T, Kalhorn TF, Watkins PB, Schuetz EG, Thummel KE: Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol. 2006 Jan;69(1):56-65. Epub 2005 Oct 5. [PubMed:16207822 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:24